Drugs / OTI-010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00081055 | — | graft versus host disease, leukemia, myelodysplastic syndrome | Mesoblast, Ltd. | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OTI-010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00081055 ↗ |
| Modality | Cell therapy | “autologous expanded mesenchymal stem cells OTI-010” NCT00081055 ↗ |
| Route | Intravenous | “OTI-010 IV 4 hours before PBSCT on day 0.” NCT00081055 ↗ |